Amerikanische Gesellschaft für Hirudotherapie

Separation of monomerizing and lysozyme activities of destabilase from medicinal leech salivary gland secretion

Basic science published in Biochem Mosc (2001)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomik & ProteomikSpeichel-PharmakologieBaskova IP et al. · Biochemistry (Mosc), 2001

Abstract

Destabilase, endo-epsilon-(gamma-Glu)-Lys-isopeptidase, was prepared from the salivary gland secretion of the medicinal leech (Hirudo medicinalis). The secretion prepared by the known method of Rigbi et al. (1987) (secretion-K) lacks the destabilase-characteristic highly specific isopeptidase activity (the D-dimer-monomerizing activity) because of its degradation by proteolytic activity (the substrate of Glp-Ala-Ala-Leu-pNA) due to contamination with leech intestinal channel contents. Therefore, we have elaborated a new technique for preparation of a true leech secretion (secretion-I). This secretion is characterized by the complete absence of the leech intestinal channel contents and has no proteolytic activity. For the first time the destabilase-specific D-dimer-monomerizing and lysozyme activities were separated by fractionation of secretion-I by HPLC gel filtration through Superose S-12. For the purified destabilase preparation, these activities were separated by reversed-phase chromatography in an acetonitrile gradient (0-60%) in the presence of 0.1% trifluoroacetic acid. The monomerizing activity of destabilase is responsible for the ability of secretion-I to dissolve stabilized fibrin via isopeptidolysis of alpha-alpha and gamma-gamma fibrin chains bound by epsilon-(gamma-Glu)-Lys-isopeptide bonds.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsEndopeptidasesFibrinLeechesMuramidaseSalivary Glands

Zusammenfassung

Secretion-I free of intestinal contaminants enables HPLC separation of destabilase's monomerizing (D-dimer cleavage) and lysozyme activities, clarifying dual-functional mechanism.

Warum dies für die Hirudotherapie relevant ist

This study focused on the biochemical preparation and characterization of destabilase from Hirudo medicinalis salivary gland secretion, addressing problems with contamination by intestinal proteolytic activity in standard preparation methods. The investigators developed a new technique to obtain uncontaminated leech secretion and, for the first time, separated the D-dimer-monomerizing activity (isopeptidase) from lysozyme activity using HPLC gel filtration and reversed-phase chromatography. This work is relevant to understanding the leech secretome's complexity, confirming that destabilase's monomerizing activity dissolves stabilized fibrin through isopeptidolysis of cross-linked fibrin chains. This is a pure biochemistry study with no clinical or in vivo component; its relevance is to the molecular characterization of leech-derived enzymes rather than to therapeutic hirudotherapy outcomes.

Zitation

Separation of monomerizing and lysozyme activities of destabilase from medicinal leech salivary gland secretion.

Baskova IP et al. · Biochemistry (Mosc), 2001

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.